Learning About Mismatch Repair From a Rare Cancer Syndrome: A LOGICal Step Forward

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Junne Kamihara

Leadership: PanTher Therapeutics (I)

Stock and Other Ownership Interests: PanTher Therapeutics (I), ROME Therapeutics (I), TellBio (I)

Honoraria: Pfizer (I), NanoString Technologies (I), Foundation Medicine (I), Ikena Oncology (I)

Consulting or Advisory Role: ROME Therapeutics (I), Tekla Capital Management (I)

Research Funding: PureTech (I), Ribon Therapeutics (I), ACD Biotechne (I)

Patents, Royalties, Other Intellectual Property: Patent on drug delivery device licensed to PanTher Therapeutics (I), Patents on repeat RNA biomarkers and therapeutics licensed to Rome Therapeutics (I), Patents on circulating tumor cell biomarkers Licensed to TellBio Inc (I)

Natalie B. Collins

Open Payments Link: https://openpaymentsdata.cms.gov/physician/977647

No other potential conflicts of interest were reported.